Jeff Cranmer
@jcranmer.bsky.social
Executive Editor, BioCentury. Host, BioCentury This Week biotech podcast. Jersey Boy happily ensconced in Cali. Princeton. SAIS. Philly Eagles. Opinions=my own.
In a BioCentury Guest Column, McKinsey alum Franck Le Deu asks, will the world's toughest arena for drug innovation go the way of EVs? & asks MNCs: Are you ready to enter the China Oktagon? Can you afford not to? Read now in front of BioCentury's paywall: www.biocentury.com/article/657621
China biopharma — enter the Oktagon
China observers call it the world’s “toughest fitness center.” Get fit here, they say, and you can take on any challenge globally.I li...
www.biocentury.com
November 18, 2025 at 1:17 AM
In a BioCentury Guest Column, McKinsey alum Franck Le Deu asks, will the world's toughest arena for drug innovation go the way of EVs? & asks MNCs: Are you ready to enter the China Oktagon? Can you afford not to? Read now in front of BioCentury's paywall: www.biocentury.com/article/657621
Richard Pazdur letter to FDA CDER staff details his management philosophy: “I will do my best to open doors for you. Let’s walk through those doorways together.” Read Pazdur's letter in full in BioCentury: www.biocentury.com/article/657570
In his own words: Pazdur’s letter to CDER staff
On his first day as director of FDA’s Center for Drug Evaluation and Research, Richard Pazdur sent a letter to staff articulating his management phi...
www.biocentury.com
November 12, 2025 at 6:36 PM
Richard Pazdur letter to FDA CDER staff details his management philosophy: “I will do my best to open doors for you. Let’s walk through those doorways together.” Read Pazdur's letter in full in BioCentury: www.biocentury.com/article/657570
Rick Pazdur takes FDA's CDER job after Kennedy pledges to shield center from political pressure. Washington Editor @steveusdin.bsky.social Usdin explores how Pazdur's past regulatory innovations and policies may read through to the new look FDA in BioCentury: www.biocentury.com/article/657564
Pazdur takes CDER job after Kennedy pledges to shield center from political pressure
In a stunning reversal, Richard Pazdur, who turned down the job last week, has agreed to serve as director of FDA’s Center for Drug Evaluation and R...
www.biocentury.com
November 12, 2025 at 1:13 AM
Rick Pazdur takes FDA's CDER job after Kennedy pledges to shield center from political pressure. Washington Editor @steveusdin.bsky.social Usdin explores how Pazdur's past regulatory innovations and policies may read through to the new look FDA in BioCentury: www.biocentury.com/article/657564
w/2nd MFN deal, Trump admin's drug pricing strategy coming into focus, but many critical parameters remain murky. The biggest unanswered Q: whether the deals are end or beginning of admin's attempts to remake the U.S. pharma market. via @steveusdin.bsky.social www.biocentury.com/article/657266
With second deal, MFN comes into focus
With a second “most favored nation” pricing deal, elements of the Trump administration’s drug pricing strategy came into focus last we...
www.biocentury.com
October 14, 2025 at 1:17 AM
w/2nd MFN deal, Trump admin's drug pricing strategy coming into focus, but many critical parameters remain murky. The biggest unanswered Q: whether the deals are end or beginning of admin's attempts to remake the U.S. pharma market. via @steveusdin.bsky.social www.biocentury.com/article/657266
Senate passed Biosecure Act Thursday evening as amendment to the National Defense Authorization Act. It's not in House version, but BioCentury's @steveusdin.bsky.social says it's likely to be included in the final version that President Trump will sign by year-end: biocentury.com/article/657251
Senate passes Biosecure legislation
The Senate passed the Biosecure Act Thursday evening as an amendment to the National Defense Authorization Act. Although the amendment was not included in ...
biocentury.com
October 10, 2025 at 1:05 AM
Senate passed Biosecure Act Thursday evening as amendment to the National Defense Authorization Act. It's not in House version, but BioCentury's @steveusdin.bsky.social says it's likely to be included in the final version that President Trump will sign by year-end: biocentury.com/article/657251
The biotech industry lost a giant last month, when David Baltimore passed away. I spoke to some of his closest friends and colleagues and wrote this remembrance (in front of our paywall).
David Baltimore's enduring legacy: Remembering 'a giant of science’: www.biocentury.com/article/656970
David Baltimore's enduring legacy: Remembering 'a giant of science’: www.biocentury.com/article/656970
David Baltimore’s enduring legacy: Remembering ‘a giant of science’
Molecular biologist David Baltimore, a Nobel laureate whose work bridged the worlds of science, medicine and public health, embodied the values that made U...
www.biocentury.com
October 8, 2025 at 10:31 PM
The biotech industry lost a giant last month, when David Baltimore passed away. I spoke to some of his closest friends and colleagues and wrote this remembrance (in front of our paywall).
David Baltimore's enduring legacy: Remembering 'a giant of science’: www.biocentury.com/article/656970
David Baltimore's enduring legacy: Remembering 'a giant of science’: www.biocentury.com/article/656970
Peter Marks has joined Eli Lilly as SVP for molecule discovery and head of infectious diseases, marking his return to industry after nearly a decade at FDA, per BioCentury's @steveusdin.bsky.social
October 7, 2025 at 5:52 PM
Peter Marks has joined Eli Lilly as SVP for molecule discovery and head of infectious diseases, marking his return to industry after nearly a decade at FDA, per BioCentury's @steveusdin.bsky.social
Seeing opportunities among headwinds, TCG X closes $1.3B 3rd fund: BioCentury's @biobonanos.bsky.social speaks with Chen Yu, who sees attractive valuations in private and public equities that could turn into strong returns and draw LPs back into biotech. www.biocentury.com/article/657171
Seeing opportunities among headwinds, TCG X closes $1.3B third fund
Despite headwinds facing the biotech industry, TCG Crossover’s Chen Yu believes the firm will deploy its new $1.3 billion fund during “a...
www.biocentury.com
October 6, 2025 at 3:08 PM
Seeing opportunities among headwinds, TCG X closes $1.3B 3rd fund: BioCentury's @biobonanos.bsky.social speaks with Chen Yu, who sees attractive valuations in private and public equities that could turn into strong returns and draw LPs back into biotech. www.biocentury.com/article/657171
Tidmarsh seems 2 be pursuing a personal agenda at FDA, with LI posts like the 1 that drove $AUPH down 16%. Under previous administrations, a CDER director who behaved this way would have been ordered to pack up and leave, writes BioCentury's @steveusdin.bsky.social www.biocentury.com/article/657149
By pursuing a personal agenda, Tidmarsh risks losing public trust: A Perspective
George Tidmarsh, director of FDA’s Center for Drug Evaluation and Research, argues FDA should be run like a biotech company, but a biotech CEO who p...
www.biocentury.com
September 30, 2025 at 11:17 PM
Tidmarsh seems 2 be pursuing a personal agenda at FDA, with LI posts like the 1 that drove $AUPH down 16%. Under previous administrations, a CDER director who behaved this way would have been ordered to pack up and leave, writes BioCentury's @steveusdin.bsky.social www.biocentury.com/article/657149
CMS to propose 'most favored nation' pricing benchmark model. White House reviewing proposed international reference pricing model. Scoop via my BioCentury colleague @steveusdin.bsky.social www.biocentury.com/article/657090
CMS to propose MFN pricing benchmark model
The Trump administration is laying the groundwork for an international reference pricing, or “most favored nation,” system for innovative med...
www.biocentury.com
September 25, 2025 at 4:15 PM
CMS to propose 'most favored nation' pricing benchmark model. White House reviewing proposed international reference pricing model. Scoop via my BioCentury colleague @steveusdin.bsky.social www.biocentury.com/article/657090
Former FDA Commish, current NEA Partner Scott Gottlieb warns U.S. against restricting in-licensing drugs from China, saying restrictions could spark 'IP arms race' that would hurt U.S. patients, industry, writes BioCentury Washington Editor @steveusdin.bsky.social: www.biocentury.com/article/657051
Gottlieb warns against restricting in-licensing drugs from China
Former FDA Commissioner Scott Gottlieb warned Friday that restrictions on in-licensing medicines from China could trigger an international IP “arms ...
www.biocentury.com
September 19, 2025 at 9:11 PM
Former FDA Commish, current NEA Partner Scott Gottlieb warns U.S. against restricting in-licensing drugs from China, saying restrictions could spark 'IP arms race' that would hurt U.S. patients, industry, writes BioCentury Washington Editor @steveusdin.bsky.social: www.biocentury.com/article/657051
$LBRX's IPO 1st to raise >$25M by a pure-play biopharma on
NASDAQ since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. LB finishes the day up 12%. Another win for CEO Heather Turner, who captained Carmot through its takeout by Roche
NASDAQ since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. LB finishes the day up 12%. Another win for CEO Heather Turner, who captained Carmot through its takeout by Roche
September 12, 2025 at 10:40 PM
$LBRX's IPO 1st to raise >$25M by a pure-play biopharma on
NASDAQ since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. LB finishes the day up 12%. Another win for CEO Heather Turner, who captained Carmot through its takeout by Roche
NASDAQ since $AARD in February & at $285M it's 2nd largest of '25 after $MTSR. LB finishes the day up 12%. Another win for CEO Heather Turner, who captained Carmot through its takeout by Roche
House passes bill seeking to end most U.S.-China academic research collabs. @steveusdin.bsky.social says like Biosecure, the SAFE Research Act is part of a trend in DC to re-define nat security to include basic, applied research on topics such as cancer www.biocentury.com/article/656978
House passes bill that would end most U.S.-China academic research collaborations
Last week, Cell published a study by researchers at the National Cancer Institute and Chinese universities who analyzed 90 datasets from 8,575 tumors to i...
www.biocentury.com
September 12, 2025 at 12:02 AM
House passes bill seeking to end most U.S.-China academic research collabs. @steveusdin.bsky.social says like Biosecure, the SAFE Research Act is part of a trend in DC to re-define nat security to include basic, applied research on topics such as cancer www.biocentury.com/article/656978
U.K. nds to find common ground with pharma on reimbursement if it wants to win the comp for life sciences investments. Fortunately for
MHRA CEO Tallon creating a world-class reg environment is less contentious. via BioCentury's @steveusdin.bsky.social www.biocentury.com/article/656960
MHRA CEO Tallon creating a world-class reg environment is less contentious. via BioCentury's @steveusdin.bsky.social www.biocentury.com/article/656960
How Tallon plans to make MHRA a pillar of U.K. life sciences competitiveness
The U.K. government will have to find common ground with pharmas on reimbursement if it wants to win the competition for life sciences investments. Fortuna...
www.biocentury.com
September 11, 2025 at 2:46 AM
U.K. nds to find common ground with pharma on reimbursement if it wants to win the comp for life sciences investments. Fortunately for
MHRA CEO Tallon creating a world-class reg environment is less contentious. via BioCentury's @steveusdin.bsky.social www.biocentury.com/article/656960
MHRA CEO Tallon creating a world-class reg environment is less contentious. via BioCentury's @steveusdin.bsky.social www.biocentury.com/article/656960
Reposted by Jeff Cranmer
A leaked memo on BIO's strategy is energizing anti-vaxxers, writes BioCentury's @steveusdin.bsky.social. The document describes BIO's investment in pro-vaccine communications, plans to engage with conservatives in and outside the Trump administration
July 2, 2025 at 1:09 AM
A leaked memo on BIO's strategy is energizing anti-vaxxers, writes BioCentury's @steveusdin.bsky.social. The document describes BIO's investment in pro-vaccine communications, plans to engage with conservatives in and outside the Trump administration
Amarin, Merck alum Karim Mikhail emerges as possible head of FDA’s CDER, reports @steveusdin.bsky.social
June 20, 2025 at 12:13 AM
Amarin, Merck alum Karim Mikhail emerges as possible head of FDA’s CDER, reports @steveusdin.bsky.social
The biopharma industry is racing to counter the Trump MFN threat: With White House demanding 85% across-the-board drug price cuts, the biopharma industry hopes to avoid catastrophic policies via alternative concessions, writes @steveusdin.bsky.social in BioCentury www.biocentury.com/article/656077
Industry races to counter Trump MFN threat
Biopharma leaders view President Donald Trump’s push for “most favored nation” drug pricing as a serious, urgent threat. While there i...
www.biocentury.com
May 31, 2025 at 1:03 AM
The biopharma industry is racing to counter the Trump MFN threat: With White House demanding 85% across-the-board drug price cuts, the biopharma industry hopes to avoid catastrophic policies via alternative concessions, writes @steveusdin.bsky.social in BioCentury www.biocentury.com/article/656077
Setback for Stealth raises questions about FDA’s implementation of rare disease policies. The biotech’s regulatory odyssey in Barth syndrome exemplifies the problems Makary has vowed to fix. @steveusdin.bsky.social Usdin takes a closer look in BioCentury: www.biocentury.com/article/656066
Stealth CRL raises questions about FDA’s implementation of rare disease policies
FDA has issued a complete response letter for elamipretide, sending patients with Barth syndrome, along with the drug’s developer, Stealth Biotherap...
www.biocentury.com
May 29, 2025 at 11:47 PM
Setback for Stealth raises questions about FDA’s implementation of rare disease policies. The biotech’s regulatory odyssey in Barth syndrome exemplifies the problems Makary has vowed to fix. @steveusdin.bsky.social Usdin takes a closer look in BioCentury: www.biocentury.com/article/656066
Biggest licensing deal yet for a China biotech asset-PFE taking rights to 3SBio bispecific-is also tied for 3rd largest asset deal ever in biotech.
This latest deal in the PD-(L)1 x VEGF space has PFE paying $1.25B u/f. Here's @biobonanos.bsky.social take www.biocentury.com/article/655979
This latest deal in the PD-(L)1 x VEGF space has PFE paying $1.25B u/f. Here's @biobonanos.bsky.social take www.biocentury.com/article/655979
In biggest licensing deal yet for a China asset, Pfizer takes rights to 3SBio’s bispecific
In the latest and largest deal between a China-based biotech and a larger biopharma for a bispecific with broad potential in oncology, Pfizer is paying 3SB...
www.biocentury.com
May 20, 2025 at 10:56 PM
Biggest licensing deal yet for a China biotech asset-PFE taking rights to 3SBio bispecific-is also tied for 3rd largest asset deal ever in biotech.
This latest deal in the PD-(L)1 x VEGF space has PFE paying $1.25B u/f. Here's @biobonanos.bsky.social take www.biocentury.com/article/655979
This latest deal in the PD-(L)1 x VEGF space has PFE paying $1.25B u/f. Here's @biobonanos.bsky.social take www.biocentury.com/article/655979
Another missed deadline by RFK Jr. & Makary's FDA
-- this time for a treatment for a very rare disease: www.biocentury.com/article/655776
-- this time for a treatment for a very rare disease: www.biocentury.com/article/655776
FDA misses PDUFA goal for Stealth’s Barth syndrome treatment
FDA has missed another PDUFA review deadline, this time for a treatment that a small biotech is developing for an ultrarare disease. Stealth Biotherapeutic...
www.biocentury.com
April 29, 2025 at 1:18 PM
Another missed deadline by RFK Jr. & Makary's FDA
-- this time for a treatment for a very rare disease: www.biocentury.com/article/655776
-- this time for a treatment for a very rare disease: www.biocentury.com/article/655776
Reposted by Jeff Cranmer
Dear Canada-
Please accept our deepest apologies from all decent Americans embarrassed by the obnoxious trolling from our man-baby-in-chief who is lacking in both intelligence & any impulse-control whatsoever.
❤️ from your neighbors below, 🇺🇸
#MakeAmericaNormalAgain
Please accept our deepest apologies from all decent Americans embarrassed by the obnoxious trolling from our man-baby-in-chief who is lacking in both intelligence & any impulse-control whatsoever.
❤️ from your neighbors below, 🇺🇸
#MakeAmericaNormalAgain
April 28, 2025 at 7:27 PM
Dear Canada-
Please accept our deepest apologies from all decent Americans embarrassed by the obnoxious trolling from our man-baby-in-chief who is lacking in both intelligence & any impulse-control whatsoever.
❤️ from your neighbors below, 🇺🇸
#MakeAmericaNormalAgain
Please accept our deepest apologies from all decent Americans embarrassed by the obnoxious trolling from our man-baby-in-chief who is lacking in both intelligence & any impulse-control whatsoever.
❤️ from your neighbors below, 🇺🇸
#MakeAmericaNormalAgain
Reposted by Jeff Cranmer
And now, a note on Bill Owens who, until this past week, was the executive producer of 60 Minutes.
We’ll be back next week with another edition of 60 Minutes.
We’ll be back next week with another edition of 60 Minutes.
April 28, 2025 at 12:38 AM
And now, a note on Bill Owens who, until this past week, was the executive producer of 60 Minutes.
We’ll be back next week with another edition of 60 Minutes.
We’ll be back next week with another edition of 60 Minutes.
At last, a biotech buy that crosses $1B
A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought: www.biocentury.com/article/6557...
Eight-year-run for Pfizer spinout Springworks culminates in Merck KGaA buyout
The takeout of Springworks by Merck KGaA will fortify the German company’s oncology business with a pair of approved drugs for rare tumors, while al...
www.biocentury.com
April 28, 2025 at 11:22 PM
At last, a biotech buy that crosses $1B
Reposted by Jeff Cranmer
A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought: www.biocentury.com/article/6557...
Eight-year-run for Pfizer spinout Springworks culminates in Merck KGaA buyout
The takeout of Springworks by Merck KGaA will fortify the German company’s oncology business with a pair of approved drugs for rare tumors, while al...
www.biocentury.com
April 28, 2025 at 7:46 PM
A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought: www.biocentury.com/article/6557...